Serum AKR1A1 Levels Predict eGFR Decline Rate in Black Americans with Type 2 Diabetes

Area of Science:

• Nephrology
• Endocrinology
• Biochemistry

Background:

• Diabetic kidney disease (DKD) disproportionately affects African Americans.
• Early identification of DKD progression biomarkers is crucial for timely intervention.
• Preventing irreversible kidney damage and function decline is a key clinical goal.

Purpose of the Study:

• To investigate AKR1A1 as a potential biomarker for early DKD progression.
• To assess the role of AKR1A1 in kidney proximal tubule cells under fatty acid stress.
• To correlate serum AKR1A1 levels with kidney function decline in African Americans with type 2 diabetes (T2D).

Main Methods:

• AKR1A1 gene knockout in human kidney proximal tubule cells.
• Cell viability assays with and without high-dose palmitate.
• Measurement of serum AKR1A1 concentrations in African American T2D patients.
• Longitudinal assessment of estimated glomerular filtration rate (eGFR) decline.

Main Results:

• AKR1A1 knockout cells exhibited reduced viability, exacerbated by palmitate.
• Higher serum AKR1A1 levels in African Americans with T2D and preserved kidney function predicted a slower eGFR decline.
• AKR1A1 appears to mitigate detrimental effects of fatty acid metabolism in kidney cells.

Conclusions:

• AKR1A1 plays a significant role in counteracting lipotoxicity in the kidney.
• Elevated AKR1A1 may serve as a protective biomarker against rapid kidney function decline in T2D.
• Further research into AKR1A1's therapeutic potential is warranted for DKD management.